Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Friday, May 25, 2018 · 448,630,564 Articles · 3+ Million Readers

DOR BioPharma Partners With Sigma-Tau Pharmaceuticals

February 13, 2009 (FinancialWire) -- DOR BioPharma, Inc. (OTCBB: DORB) (Current Market Cap: US$14.76 Bil.) said that it has signed a potential $30 million partnering agreement with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization in North America of orBec.

As part of the agreement, Sigma-Tau will make a $6 million upfront investment in DOR, inclusive of $1.5 million that was recently completed under a letter of intent dated November 26, 2008. The remaining $4.5 million investment was priced at a 50% premium to the five day trailing average of DOR stock, putting the investment price at $0.18 per share.

Sigma-Tau will also make payments to DOR totaling $10 million, subject to the achievement of certain milestones. The first of these, a $1 million payment, will be made upon the enrollment of the first patient in DOR's upcoming confirmatory Phase 3 clinical trial of orBec for the treatment of acute gastrointestinal Graft-versus-Host disease, which is scheduled to occur in the first half of 2009.

In exchange for commercialization rights, Sigma-Tau will pay DOR a 35% royalty on net sales, under which DOR will supply the drug product while maintaining worldwide manufacturing rights. Commercialization expense, including launch activities, could potentially reach $15 million by the end of the first year after launch. Additionally, DOR will grant Sigma-Tau a seat on its board.

According to Ewing, New Jersey-based DOR, orBec represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where GVHD is most frequently encountered and highly problematic.

FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .

Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .

Copyright(C)2009 by financialwire.net, Inc. All rights reserved.

Powered by EIN Presswire